VOR Projected Dividend Yield
Vor Biopharma Inc ( NASDAQ : VOR )Vor Biopharma is a cell therapy company. Co.'s primary focus is on patients suffering from acute myeloid leukemia (AML). Co. develops treatments for patients suffering from hematological malignancies. Co. is developing its primary eHSC product candidate, VOR33, which it has potential to transform the treatment for AML and other blood cancers. CD33 is a clinically validated target for AML. Co. has initiated VBP101, a Phase 1/2a clinical trial in patients with CD33-positive AML who are at high risk of relapse. Co. is also developing its Treatment System comprising the VOR33-CLL1 multiplex-edited eHSC therapy and the VCAR33-CLL1 multi-specific CAR-T therapy. 20 YEAR PERFORMANCE RESULTS |
VOR Dividend History Detail VOR Dividend News VOR Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |